NO20022898L - Sammensetning for cellespesifikk transfer av aktive substanser - Google Patents

Sammensetning for cellespesifikk transfer av aktive substanser

Info

Publication number
NO20022898L
NO20022898L NO20022898A NO20022898A NO20022898L NO 20022898 L NO20022898 L NO 20022898L NO 20022898 A NO20022898 A NO 20022898A NO 20022898 A NO20022898 A NO 20022898A NO 20022898 L NO20022898 L NO 20022898L
Authority
NO
Norway
Prior art keywords
molecules
several
cell
composition
active substances
Prior art date
Application number
NO20022898A
Other languages
English (en)
Other versions
NO20022898D0 (no
Inventor
Wolfgang Lueke
Harald Petry
Oliver Ast
Inge Wilke
Claudia Goldmann
Kerstin Wagner
Matthias Schnabelrauch
Original Assignee
Jenapharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh filed Critical Jenapharm Gmbh
Publication of NO20022898D0 publication Critical patent/NO20022898D0/no
Publication of NO20022898L publication Critical patent/NO20022898L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Seeds, Soups, And Other Foods (AREA)
NO20022898A 2001-06-28 2002-06-17 Sammensetning for cellespesifikk transfer av aktive substanser NO20022898L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10131145A DE10131145B4 (de) 2001-06-28 2001-06-28 Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen

Publications (2)

Publication Number Publication Date
NO20022898D0 NO20022898D0 (no) 2002-06-17
NO20022898L true NO20022898L (no) 2002-12-30

Family

ID=7689740

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022898A NO20022898L (no) 2001-06-28 2002-06-17 Sammensetning for cellespesifikk transfer av aktive substanser

Country Status (7)

Country Link
US (1) US20030044961A1 (no)
EP (1) EP1270586B1 (no)
JP (1) JP2003061693A (no)
AT (1) ATE346859T1 (no)
DE (2) DE10131145B4 (no)
ES (1) ES2275781T3 (no)
NO (1) NO20022898L (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10306789A1 (de) * 2003-02-18 2004-08-26 Responsif Gmbh Zusammensetzung zur Verabreichung an ein Lebewesen und Verfahren zur Markierung von Mitteln
US7468186B2 (en) * 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
NZ594973A (en) 2009-02-05 2012-05-25 Biogen Idec Inc Methods for the detection of JC polyomavirus and diagnosis of progressive multifocal leukoencephalopathy (PML)
EP2289937A1 (en) 2009-08-24 2011-03-02 Wilfried Stücker Production of monoclonal antibodies in vitro
EP2548567A1 (en) * 2011-07-22 2013-01-23 Universitätsklinikum Hamburg-Eppendorf Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
EP2554664A1 (de) 2011-08-02 2013-02-06 Life Science Inkubator Verfahren zur Aufreinigung von Virus-ähnlichen Partikeln (VLP)
EP2636746A1 (en) * 2012-03-06 2013-09-11 Life Science Inkubator A novel drug delivery system based on JCV-VLP
EP2774991B1 (en) * 2013-03-06 2017-12-06 Life Science Inkubator Betriebs GmbH & Co. KG Drug delivery system for use in the treatment or diagnosis of neurological disorders
EP3031821A1 (en) * 2014-12-08 2016-06-15 Life Science Inkubator polyomavirus VLPs with a fusion protein
EP3031820A1 (en) * 2014-12-08 2016-06-15 Life Science Inkubator JC Polyomavirus VLP (virus-like particle) with a targeting peptide
CN105194681B (zh) * 2015-09-17 2018-02-09 哈尔滨医科大学 一种基于ppv病毒样颗粒的纳米递药系统及其制备方法和应用
US20180320199A1 (en) 2015-10-28 2018-11-08 Life Science Inkubator Gmbh Use of vlp for the detection of nucleic acids
WO2018141849A1 (en) 2017-02-02 2018-08-09 Deutsches Primatenzentrum Gmbh (Dpz) - Leibniz-Institut Für Primatenforschung RETARGETING OF VIRUSES OR VLPs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093920A (en) * 1987-06-25 1992-03-03 At&T Bell Laboratories Programmable processing elements interconnected by a communication network including field operation unit for performing field operations
DE4335025A1 (de) * 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
US6613749B1 (en) * 1994-07-26 2003-09-02 Imperial College Innovations Limited Papovavirus pseudocapsids and use thereof for exogenous material transfer
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6287857B1 (en) * 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
JP2001222564A (ja) * 2000-02-09 2001-08-17 Hitachi Ltd 論理エミュレーションシステム
JP2001249824A (ja) * 2000-03-02 2001-09-14 Hitachi Ltd 論理エミュレーションプロセッサおよびそのモジュールユニット
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
WO2002024232A2 (en) * 2000-09-25 2002-03-28 Board Of Regents, The University Of Texas System Pei: dna vector formulations for in vitro and in vivo gene delivery
US7223388B2 (en) * 2001-08-03 2007-05-29 Board Of Regents, The Univeristy Of Texas System Modified reoviral therapy

Also Published As

Publication number Publication date
DE10131145B4 (de) 2005-07-14
EP1270586B1 (de) 2006-11-29
DE10131145A1 (de) 2003-03-06
ATE346859T1 (de) 2006-12-15
JP2003061693A (ja) 2003-03-04
EP1270586A2 (de) 2003-01-02
US20030044961A1 (en) 2003-03-06
DE50208824D1 (de) 2007-01-11
EP1270586A3 (de) 2003-10-15
NO20022898D0 (no) 2002-06-17
ES2275781T3 (es) 2007-06-16

Similar Documents

Publication Publication Date Title
NO20022898D0 (no) Sammensetning for cellespesifikk transfer av aktive substanser
EP1131333A4 (en) INSULATED NUCLEIC ACID MOLECULES ENCODING INDUCIBLE FACTORS DERIVED FROM T-CELL (TIF), ENCODED PROTEINS AND USE THEREOF
Boyd-Franklin et al. Spirituality and religion: Implications for psychotherapy with African American clients and families.
DE69828045D1 (de) Verbindungen, ihre herstellung und ihre verwendung für den transfer von nucleinsäuren in zellen
ZA200405390B (en) Entrapped binding proteins as biosensors
ATE430558T1 (de) Herstellung von mikrokügelchen
DK1681353T3 (da) Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
PT1016711E (pt) Processo de inactivacao de virus de envelope numa preparacao viral de adenovirus
ATE411001T1 (de) Immunmodulations-vorrichtung zur verwendung in tieren
EA200000007A1 (ru) Регуляция экспрессии хинолятфосфорибозил-трансферазы
BR9905110A (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas
EP1165586A4 (en) TCL-1B GENES AND PROTEINS AND RELATED METHODS AND METHODS
DE60227718D1 (de) Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen
DE60013021D1 (de) Herstellung von S,S und R,S Aminosäuren-Isosteren
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
DE69837190D1 (de) Elektroden-Materialien zur Verwendung in Batterien,und Elektroden und Batterien, in denen diese verwendet werden
WO1997011667A3 (en) Therapeutic applications using horse serum
ATE223701T1 (de) Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
DE10294286D2 (de) Herstellung von trägergebundenen Molekülen
ATE263234T1 (de) Veränderte, kleine rna-viren
AU3609800A (en) Novel formulations of alkyllithiums with improved thermal stability, processes to produce these formulations and processes for using the same to improve stability of living polymer chain ends
DE60033679D1 (de) Herstellung von rekombinanten adenoviren und von adenovirus-genbanken
EE03922B1 (et) 3-N,N-ditsüklobutüülamino-8-fluoro-3,4-dihüdro-2H-1-bensopüraan-5-karboksamiidi, selle R-enantiomeeri ja S-enantiomeeri valmistamise meetod
EP1315794A4 (en) Genetic demonstration of requirement for nkx6.1, nkx2.2 and nkx6.2 in ventral neuron generation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application